Inspection Report

Ararat Nursing Facility: Medication Monitoring Failures CA

October 12, 2025

Mission Hills, CA

294 views

MISSION HILLS, CA - A recent state inspection at Ararat Nursing Facility identified critical medication oversight failures, including the facility's inability to properly monitor psychotropic drugs and respond to pharmacist recommendations for medication review.

Failure to Address Pharmacist's Medication Safety Concerns

State inspectors discovered that facility staff and physicians failed to respond to a consulting pharmacist's recommendation for medication review within the required timeframe. The case involved a resident who had been taking Trazadone, an antidepressant medication also used for sleep disorders, for over a year without proper evaluation for dose reduction.

On July 4, 2024, the consulting pharmacist submitted a formal note to the attending physician requesting assessment of whether a gradual dose reduction (GDR) would be clinically appropriate for a resident who had been receiving Trazadone 75 milligrams at bedtime since June 18, 2023. Federal nursing regulations require facilities to attempt gradual dose reductions in two separate quarters within the first year of psychotropic medication use, with at least one month between attempts.

The pharmacist's note specifically stated: "This resident continues on Trazadone 75mg qhs from 6/18/2023. The Federal nursing regulations require that a gradual dose reduction (GDR) be attempted in two separate quarters (with at least one month between attempts) within the first year in which a resident receives psychopharmacological medication."

However, more than 30 days passed without any documented physician response or clinical justification for continuing the medication at its current dose. During the August 2024 inspection, inspectors found no evidence that the attending physician had reviewed or addressed the pharmacist's recommendation.

Understanding the Medical Significance of Psychotropic Medication Monitoring

Psychotropic medications like Trazadone affect brain chemistry and can significantly impact a resident's mental, emotional, and behavioral state. These medications carry substantial risks, particularly for elderly nursing home residents who may be more susceptible to side effects including confusion, falls, sedation, and cardiovascular complications.

The requirement for gradual dose reduction attempts exists because many residents may improve over time and no longer need the same level of medication. Regular medication review helps ensure residents receive the lowest effective dose necessary for their condition, reducing the risk of adverse effects while maintaining therapeutic benefits.

Trazadone specifically can cause drowsiness, dizziness, and coordination problems that increase fall risk in elderly residents. It can also interact with other medications commonly prescribed to nursing home residents, potentially leading to dangerous drug interactions.

Breakdown in Medication Oversight System

The facility's own policy, titled "Drug Regimen Review" and dated November 1, 2017, clearly outlined the requirements for medication monitoring. According to this policy, the facility was required to maintain residents' "highest practicable level of physical, mental and psychosocial well-being" through proper oversight by licensed pharmacists, attending physicians, medical directors, and nursing leadership.

The policy specifically stated that consulting pharmacists must review each resident's medication regimen monthly to identify irregularities and potential adverse consequences. When irregularities are identified, they must be reported to the attending physician, medical director, and Director of Nursing, and "these reports must be acted upon."

The facility's own procedures required attending physicians to respond to pharmacist irregularities within 30 days, documenting either what action was taken or providing clinical rationale if no changes were made. This 30-day requirement was emphasized during an interview with the Director of Nursing, who acknowledged that timely review was "important to ensure residents were receiving treatment that was optimal for their condition and to maintain their highest level of well-being."

Medical Record Documentation Reveals Concerning Pattern

Medical records showed that the resident in question had been diagnosed with depression and was originally prescribed Trazadone for "depression manifested by constant health complaints and insomnia." However, the facility's Medication Administration Record for July 2024 showed no documented episodes of insomnia between July 1 and July 31, 2024, raising questions about whether the medication was still medically necessary.

This pattern suggests the resident's sleep difficulties may have improved, potentially supporting the pharmacist's recommendation for a dose reduction trial. Without proper physician review and documentation, however, the facility continued administering the medication at its original dose.

Industry Standards for Psychotropic Medication Management

Current healthcare standards emphasize the principle of using the lowest effective dose of psychotropic medications for the shortest duration necessary. This approach, known as "start low, go slow," is particularly important in elderly populations where medication sensitivity is heightened.

Best practices for psychotropic medication management in nursing homes include regular reassessment of medication necessity, systematic attempts at dose reduction when clinically appropriate, careful monitoring for side effects, and comprehensive documentation of all clinical decisions.

The Centers for Medicare & Medicaid Services has established specific guidelines requiring facilities to implement gradual dose reductions and consider non-pharmacological interventions before continuing or initiating psychotropic medications. These requirements reflect growing recognition of the risks associated with long-term psychotropic medication use in elderly residents.

Potential Health Consequences of Inadequate Monitoring

The inspection findings indicate that inadequate medication monitoring placed the resident at risk for "significant adverse consequences from the use of unnecessary psychotropic medications, which could result in impairment or decline in the residents' mental, physical condition, functional, and psychosocial status."

Unnecessary psychotropic medication use can lead to various complications including cognitive impairment, increased fall risk, cardiovascular effects, and decreased quality of life. For elderly nursing home residents, these risks are particularly concerning as they may compound existing health conditions and functional limitations.

Additionally, failure to attempt dose reductions when appropriate may result in residents receiving higher doses than necessary, increasing the likelihood of adverse effects while potentially preventing the identification of residents who could function well with reduced medication or alternative treatments.

Additional Issues Identified

The inspection also revealed related deficiencies in the facility's drug regimen review process, classified under regulatory code F756. These findings highlighted broader systemic issues with medication oversight and the facility's failure to follow its own established policies for responding to pharmacist recommendations.

The violations were classified as causing "minimal harm or potential for actual harm" affecting "few" residents, suggesting the issues were identified before causing serious injury but represented significant compliance failures that required immediate correction.

The inspection findings underscore the critical importance of robust medication monitoring systems in nursing homes, where residents depend on facility staff and healthcare providers to ensure their medications remain appropriate and safe throughout their stay.

Full Inspection Report

The details above represent a summary of key findings. View the complete inspection report for Ararat Nursing Facility from 2024-08-09 including all violations, facility responses, and corrective action plans.

Additional Resources

Editorial Standards

Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).

Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.

Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.

Last verified: June 20, 2026 · Our methodology

Quick Answer

Ararat Nursing Facility in MISSION HILLS, CA was cited for violations during a health inspection on August 9, 2024.

The pharmacist's note specifically stated: "This resident continues on Trazadone 75mg qhs from 6/18/2023.

Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.

Frequently Asked Questions

What happened at Ararat Nursing Facility?

The pharmacist's note specifically stated: "This resident continues on Trazadone 75mg qhs from 6/18/2023.

How serious are these violations?

Violation severity varies from minor documentation issues to serious safety concerns. Review the inspection report for specific deficiency codes and scope. All violations must be corrected within required timeframes and are subject to follow-up verification inspections.

What should families do?

Families should: (1) Ask facility administration about specific corrective actions taken, (2) Request to see the follow-up inspection report verifying corrections, (3) Check if this represents a pattern by reviewing prior inspection reports, (4) Compare this facility's ratings with other nursing homes in MISSION HILLS, CA, (5) Report any new concerns directly to state authorities.

Where can I see the full inspection report?

The complete inspection report is available on Medicare.gov's Care Compare website (www.medicare.gov/care-compare). You can also request a copy directly from Ararat Nursing Facility or from the state Department of Health. The report includes specific deficiency codes, facility responses, and correction timelines. This facility's federal provider number is 555579.

Has this facility had violations before?

To check Ararat Nursing Facility's history, visit Medicare.gov's Care Compare and review their inspection history, quality ratings, and staffing levels. Look for patterns of repeated violations, especially in critical areas like abuse prevention, medication management, infection control, and resident safety.